Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version
SECTIONS
- General Information About Late Effects of Treatment for Childhood Cancer
- Subsequent Neoplasms
- Late Effects of the Cardiovascular System
- Late Effects of the Central Nervous System
- Late Effects of the Digestive System
- Late Effects of the Endocrine System
- Late Effects of the Immune System
- Late Effects of the Musculoskeletal System
- Late Effects of the Reproductive System
- Late Effects of the Respiratory System
- Late Effects of the Special Senses
- Late Effects of the Urinary System
- Changes to This Summary (01/02/2018)
- About This PDQ Summary
- View All Sections
Changes to This Summary (01/02/2018)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Bhakta et al. as reference 15.
Added text to state that using the cumulative burden metric—which incorporates multiple health conditions and recurrent events into a single metric that takes into account competing risks—by age 50 years, survivors in the St. Jude Lifetime Cohort experienced an average of 17.1 chronic health conditions, 4.7 of which were severe/disabling, life threatening, or fatal. This is in contrast to the cumulative burden in matched community controls who experienced 9.2 chronic health conditions, 2.3 of which were severe/disabling, life threatening, or fatal.
Added Figure 1 depicting the distribution of cumulative burden by age among childhood cancer survivors of specific pediatric cancer subtypes and community controls participating in St. Jude Lifetime Cohort Study.
Added text about the results of a follow-up Childhood Cancer Survivor Study that evaluated morbidity and mortality associated with meningioma among 4,221 participants treated with cranial radiation therapy (cited Bowers et al. as reference 7).
Added text about the results of a Dutch study that evaluated the contribution of chemotherapy to solid cancer risk in a large cohort of childhood cancer survivors diagnosed between 1963 and 2001.
Added text to state that in a population-based study of 69,460 5-year survivors of cancer diagnosed before age 20 years, the risk of subsequent primary bone cancer was 22-fold greater than that of the general population, with an estimated 45-year cumulative incidence of 0.6%, compared with an expected rate of 0.03% in the general population. The observed excess numbers of subsequent primary bone cancer declined with both age and years from diagnosis (cited Fidler et al. as reference 55).
Added text about the results of a Dutch study that investigated the risk of sarcoma in a large cohort of childhood cancer survivors diagnosed between 1963 and 2001.
Added Wang et al. as reference 80.
Added text about the results of a St. Jude Lifetime Cohort Study that compared the prevalence of major and minor electrocardiography (ECG) abnormalities among 2,715 participants and 268 community controls (cited Mulrooney et al. as reference 19).
Added text about the results of a Teenage and Young Adult Cancer Survivor Study that investigated cardiac mortality in more than 200,000 5-year survivors of adolescent and young adult cancer (cited Henson et al. as reference 20).
Added van Dijk et al. as reference 51.
Added text about the results of a Teenage and Young Adult Cancer Survivor Study that evaluated the risk of hospitalization for a cerebrovascular event among 5-year survivors of cancer diagnosed at age 15 to 39 years (cited Bright et al. as reference 55).
This section was comprehensively reviewed, extensively revised, and reformatted.
Added text about the results of a French study that evaluated the overall and age-specific prevalence of and risk factors for metabolic syndrome and its components among 650 adult survivors of childhood leukemia treated without hematopoietic stem cell transplantation (cited Saultier et al. as reference 71).
This section was comprehensively reviewed, extensively revised, and reformatted.
This section was comprehensively reviewed, extensively revised, and reformatted.
Added text about the results of a nationwide Finnish population-based registry study that compared the risk of congenital anomalies in the offspring of 6,862 long-term survivors of childhood, adolescent, and young adult cancer treated between 1953 and 2004 with the risk of congenital anomalies in the offspring of 35,690 siblings (cited Seppänen et al. as reference 71).
This section was comprehensively reviewed, extensively revised, and reformatted.
Revised text to state that a higher cumulative dose of platinum-based chemotherapy (≥300 mg/m2) is a risk factor associated with hearing loss (cited Clemens et al. as reference 5).
Added text to state that in a cross-sectional, multicenter analysis that included 451 Dutch childhood cancer survivors who received platinum agents but not cranial radiation therapy, the incidence of ototoxicity associated with the use of carboplatin given alone was 17%.
This section was comprehensively reviewed, extensively revised, and reformatted.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
.png)
No hay comentarios:
Publicar un comentario